In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Teligent, Inc.

https://www.teligent.com/

Latest From Teligent, Inc.

Generics Industry Experiences Extraordinary First Quarter Due To COVID-19 Crisis

Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.  

Coronavirus COVID-19 Generic Drugs

Teligent Moves To Consolidate Shares To Stay Listed

Teligent has followed through with plans to condense its outstanding shares to raise their value and maintain a stock-exchange listing. Meanwhile, the company revealed a sizeable loss for the first quarter of this year, as it gave the latest on its warning letter-stricken facility in Buena, New Jersey.

Strategy Compliance

Despite New Launches, Teligent Sees A Disappointing Q4

Amid poor quarterly results, Teligent continues to focus on resolving a warning letter from the FDA, passing a pre-approval inspection of its new injectables manufacturing facility in Buena, New Jersey and managing cash flow under its new CEO.

Sales & Earnings Strategy

Who’s Hired? Teligent And Centrient Get New CEOs

Teligent CEO Jason Grenfell-Gardner has stepped down with immediate effect, while Centrient CEO Karl Rotthier is preparing to leave the role in March. Both firms have announced details of their replacements. Meanwhile, Stada has appointed a new chief financial officer.

Appointments Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • IGI Laboratories, Inc. (IGI)
    • Alveda Pharmaceuticals, Inc.
UsernamePublicRestriction

Register